TABLE 3.

APC from mice given MIP-1α but not MIP-2 augment DO11.10 TCR T-cell proliferation and cytokine production following stimulation of OVA_323–339

Treatment	Lymphoproliferation (cpm)a of cells after stimulation with OVA323–339 at (μg/ml):			Cytokine production (pg/ml)b
	0.0	5.0	10.0	IL-2	IFN-γ
pCI-neo	379 ± 257	16,345 ± 1,115	21,401 ± 4,317	4,307 ± 677	243 ± 93
MIP-1α	572 ± 301	27,454 ± 2,469c	39,362 ± 5,276c	8,603 ± 532d	615 ± 218e
MIP-2	457 ± 291	21,936 ± 3,827	25,006 ± 4,192	4,793 ± 1,238	353 ± 120

^aDO11.10 TCR T cells were enriched from the spleens of DO11.10-Tg mice using a nylon wool column and used as responder cells. APC taken from mice given MIP-1α or MIP-2 DNA were irradiated and pulsed with OVA_323–339 in serum-free medium for 60 min. The OVA_323–339-treated APCs were extensively washed and used as stimulator cells. OVA_323–339-pulsed APCs were mixed with enriched DO11.10 TCR T cells and incubated for 3 days. [³H]thymidine was added to each well 18 h before harvest. The results show mean cpm ± standard deviation for three independent experiments. 

^bFollowing in vitro stimulation of DO11.10 TCR T cells with OVA_323–339 (5.0 μg/ml)-pulsed APCs, the cytokine concentration in the culture supernatant was determined by ELISA. The data represent mean ± standard deviation for three independent experiments. 

^cStatistically significant between control vector pCI-neo and MIP-1α (P = 0.004). 

^dStatistically significant between control vector pCI-neo and MIP-1α (P < 0.001). 

^eStatistically significant between control vector pCI-neo and MIP-1α (P = 0.01).